Correlation between nivolumab serum concentration and patients’/treatment characteristics
| Parameter | N | Median nivolumab concentration (µg/mL) (IQR) | P value |
| Complete response | |||
| Yes | 6 | 38.9 (37.5–42.1) | 0.024 |
| No | 82 | 31.8 (22.0–37.4) | |
| Colitis | |||
| Yes | 16 | 24.6 (16.3–36.3) | 0.09 |
| No | 64 | 33.0 (26.0–37.7) | |
| Nivolumab regimen | |||
| 3 mg/kg | 58 | 32.6 (26.2–37.5) | 0.38 |
| 240 mg | 11 | 33.7 (22.1–38.3) | |
| 480 mg | 19 | 23.9 (19.1–36.4) | |
| BMI | |||
| Normal | 24 | 35.8 (29.5–37.7) | 0.07 |
| Overweight | 36 | 32.6 (27.6–36.8) | |
| Obesity | 28 | 24.6 (18.3–37.3) |
BMI, body mass index.